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ABSTRACT: Assaying lipolytic enzymes is extremely challenging because they act on water-insoluble lipid substrates, which
are normally components of micelles, vesicles, and cellular membranes. We extended a new lipidomics-based liquid
chromatographic−mass spectrometric assay for phospholipases A2 to perform inhibition analysis using a variety of commercially
available synthetic and natural phospholipids as substrates. Potent and selective inhibitors of three recombinant human
enzymes, including cytosolic, calcium-independent, and secreted phospholipases A2 were used to establish and validate this
assay. This is a novel use of dose−response curves with a mixture of phospholipid substrates, not previously feasible using
traditional radioactive assays. The new application of lipidomics to developing assays for lipolytic enzymes revolutionizes in
vitro testing for the discovery of potent and selective inhibitors using mixtures of membranelike substrates.
■ INTRODUCTION
Assaying the activity of phospholipases A2 (PLA2s) has been
challenging because they are water-soluble enzymes acting on
water-insoluble phospholipid substrates.1,2 To set up a
successful PLA2 assay, one must consider three critical issues.
First, a suitable phospholipid substrate must be used because
there is a variety of available phospholipids. Second,
phospholipids exist in aggregated forms in water and so the
appropriate physical form should be employed. Third, a
sensitive detection system must be used that is compatible with
the substrate.3 Traditional PLA2 assays have employed
synthetic radio-labeled phospholipids that contain 3H- or
14C-labeled fatty acids (FAs) at the sn-2 position of the
phospholipid. Such phospholipids are challenging to synthe-
size, expensive, and limited in terms of commercial availability,
and they require special handling techniques.4 These
limitations pose significant difficulties in choosing an optimum
substrate for each of the various types of PLA2s. The surface-
dilution kinetics model was successfully employed by our
laboratory to explain the action of PLA2 enzymes on
phospholipid/detergent mixed micelles.5,6 The success of the
surface dilution model to explain kinetics of PLA2 enzymes in
mixed micelles, the stability of the micelle structure in the
presence of various phospholipids or inhibitors, and high
efficiency in preparing mixed micelles make them a suitable
physical form of a substrate to employ in a PLA2 assay.
7
Lipidomics-based liquid chromatographic−mass spectrometric
(LC−MS) approaches have proven to be very powerful in
understanding how PLA2 enzymes regulate eicosanoid biosyn-
thesis.8,9 LC−MS provides a very sensitive detection system
that is compatible with mixed micelles in the presence of a
surfactant.
A novel lipidomics-based PLA2 assay using mixed micelles
was previously developed for substrate specificity studies on
three human enzymes including group IVA cytosolic (cPLA2),
group VIA calcium-independent (iPLA2), and group V
secreted PLA2 (sPLA2).
10 This assay is semi-high throughput,
uses significantly smaller amounts of substrate and enzyme
compared to existing assays,3,4 and allows the use of a wide
variety of natural and synthetic unlabeled phospholipids. In the
current study, we have further developed our assay to obtain
inhibitory dose−response curves using a variety of pure
phospholipids, not previously feasible using traditional radio-
active assays. Three potent and selective inhibitors, one each
specific for cPLA2, iPLA2, and sPLA2, were employed to
validate the use of the assay for inhibitor studies. The ability to
employ lipidomics techniques in assaying PLA2 enzymes
allowed us for the first time to perform more complex
inhibitory assessments with mixtures of phospholipids.
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Determining XI(50) and IC50 values using a membranelike
substrate is now feasible, which should aid in identifying potent
and selective inhibitors for PLA2 enzymes that are necessary
for the development of new therapeutics.
■ RESULTS AND DISCUSSION
Assay Development and Validation. A lipidomics-based
high-performance LC (HPLC)−MS assay using hydrophilic
interaction chromatography (HILIC) and multiple reaction
monitoring (MRM), which allowed quantification of a variety
of lysophospholipid products, was previously developed by us
and employed to define the substrate specificity for cPLA2,
iPLA2, and sPLA2 (Figure 1A).
10 We have now used and also
extended the assay to use C18 reversed-phase chromatography
for the quantification of free FA products, including
arachidonic acid (AA), deuterated AA (AA-d8), and linoleic
acid (LA, Figure 1B). 17:0 LPC and AA-d8 were used as
internal standards for normalizing variations related to sample
handling, ionization efficiency, and signal intensity fluctuations.
Lysophospholipids and free FAs were detected using the
positive and negative ion mode, respectively.10
Three inhibitors were used to develop and validate the PLA2
assay: pyrrophenone, which is a pyrrolidine cPLA2 inhibitor;
11
OTFP, which is a fluoroketone iPLA2 inhibitor;
12 and
Ly315920, which is an indole sPLA2 inhibitor.
13 For each
inhibitor, three dose−response inhibition curves were gen-
erated for calculating XI(50) and IC50 values: two by using
lipidomics assays (one measuring lysophospholipid product in
the positive ion mode and one the FA product in the negative
ion mode) and one by using the traditional radioactive assay.
XI(50) is the mole fraction of the inhibitor in the total
substrate interface required to inhibit the enzyme by 50%.14
XI(50) and IC50 values were calculated by plotting the
percentage of inhibition versus log (mole fraction) or log
(concentration), respectively. For the radioactive assay, a
phospholipid substrate containing 14C-labeled AA esterified at
Figure 1. Quantification of primary and internal standards using HPLC chromatography and MRM: (A) for lysophospholipids using a HILIC
column (adapted from ref 10) and (B) for free FAs using a C18 reversed-phase column.
Figure 2. Dose−response inhibition curves for pyrrophenone using PAPC substrate. (A) Activity of cPLA2 was measured by detecting 16:0 LPC in
a positive ion mode and (B) by detecting free AA in a negative ion mode. (C) Activity of the enzyme was measured using 14C-labeled AA in a
scintillation counter.
Figure 3. Dose−response inhibition curves for OTFP using PAPC substrate. (A) Activity of iPLA2 was measured by detecting 16:0 LPC in a
positive ion mode and (B) by detecting free AA in a negative ion mode. (C) Activity of the enzyme was measured using 14C-labeled AA in a
scintillation counter.
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the sn-2 position was used. Free 14C-labeled AA was detected
using a scintillation counter. Mixed micelles were prepared
using 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
(PAPC) and C12E8 surfactant. PAPC was chosen as a
substrate because cPLA2 is selective for AA at the sn-2 position
and to have a common substrate for comparison of our results
because iPLA2 and sPLA2 exhibit fair activity toward this
substrate. Figures 2−4 show the dose−response curves for
Figure 4. Dose−response inhibition curves for Ly315920 using PAPC substrate. (A) Activity of sPLA2 was measured by detecting 16:0 LPC in a
positive ion mode and (B) by detecting free AA in a negative ion mode. (C) Activity of the enzyme was measured using 14C-labeled AA in a
scintillation counter.
Table 1. XI(50) and IC50 (μM) Values of PLA2 Inhibitors
aPLA2 activity was measured by detecting 16:0 lysophospholipid product in a positive ion mode.
bPLA2 activity was measured by detecting free FA
product in a negative ion mode. cPLA2 activity was measured by using
14C-labeled AA.
Table 2. XI(50), IC50, and Standard Error Values for the Inhibition of cPLA2 by Pyrrophenone, iPLA2 by OTFP, and sPLA2 by
Ly315920, Respectively, Calculated by Performing Three Independent Dose−Response Inhibition Experiments on Each
Inhibitor
pyrrophenone OTFP LY315920
positive negative positive negative positive negative
XI(50) IC50 (μM) XI(50) IC50 (μM) XI(50) IC50 (μM) XI(50) IC50 (μM) XI(50) IC50 (μM) XI(50) IC50 (μM)
0.0027 1.83 0.0027 1.88 0.00008 0.054 0.00007 0.049 0.00015 0.104 0.00019 0.131
0.0019 1.32 0.0020 1.38 0.00008 0.058 0.00009 0.060 0.00018 0.124 0.00018 0.127
0.0023 1.61 0.0021 1.47 0.00007 0.051 0.00005 0.034 0.00017 0.116 0.00020 0.136
average 0.0023 1.59 0.0023 1.58 0.00008 0.055 0.00007 0.048 0.00017 0.114 0.00019 0.131
STDEV 0.0004 0.26 0.0004 0.27 0.000005 0.004 0.00002 0.013 0.00001 0.010 0.00001 0.004
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pyrrophenone, OTFP, and Ly315920, respectively. XI(50)
values of 0.0026 (IC50 = 1.83 μM) and 0.0027 (IC50 = 1.88
μM) were calculated for pyrrophenone using the lipidomics
assay in positive and negative ion mode, respectively (Figures
2A,B). An XI(50) value of 0.0022 (IC50 = 1.23 μM) was
determined for the same inhibitor using the radioactive assay
(Figure 2C). The XI(50) values for OTFP were 0.00008 (IC50
= 0.054 μM) and 0.00007 (IC50 = 0.049 μM) using the
lipidomics assay (Figure 3A,B) and 0.00009 (IC50 = 0.048
μM) using the radioactive assay (Figure 3C). Finally, XI(50)
values of 0.00015 (IC50 = 0.104 μM) and 0.00018 (IC50 =
0.131 μM) (Figure 4A,B) were determined for Ly315920 using
the lipidomics assay and 0.00010 (IC50 = 0.056 μM) using the
radioactive assay (Figure 4C). The XI(50) and IC50 values that
were determined using the lipidomics and radioactive assays
were very similar for each of the three inhibitors within the
calculated experimental error, indicating the validity of the
lipidomics assays (Table 1).
To further assess the accuracy of lipidomics assays, three
independent dose−response inhibition experiments were
performed for each inhibitor (Figures S1−S3). The reported
average XI(50), IC50, and the standard error values indicate the
reproducibility, robustness, and accuracy of the lipidomics
assay (Table 2).
Substrate Affinity Affects Competitive Inhibitors. The
identification of a variety of lysophospholipid and free FA
products using LC−MS (Figure 1) enabled us to perform
dose−response inhibition curves by using phospholipid
substrates with a better affinity toward these enzymes. On
the basis of substrate specificity data, sPLA2 showed
approximately 27-fold greater activity toward phospholipids
containing phosphoglycerol (PG) compared to PAPC.10 The
dose−response inhibition studies of Ly315920 in the presence
of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoglycerol
(PAPG) gave XI(50) values of 0.026 (IC50 = 18 μM) and
0.032 (IC50 = 22 μM) in positive and negative ion modes,
respectively (Figure 5A,B). Ly315920 showed approximately a
170-fold higher inhibitory potency toward sPLA2 when PAPC
was utilized as a substrate versus PAPG. iPLA2 exhibited
approximately fourfold higher activity toward phospholipids
containing linoleic (L) acid at the sn-2 position rather than
AA.10 XI(50) values of 0.00012 (IC50 = 0.083 μM) and
0.00010 (IC50 = 0.067 μM) were determined for OTFP in
positive and negative ion modes, respectively, by using PLPC
as a substrate (Figure 6A,B). OTFP exhibited approximately
twofold greater inhibitor potency toward iPLA2 when PAPC
was used as a substrate versus PLPC. These two examples
demonstrate that the inhibitory potency is dependent on the
substrate affinity when it comes to competitive inhibitors.
Inhibition Studies on Membranelike Mixtures of
Substrates. PLA2 enzymes are localized on different cellular
membranes where they encounter different substrates depend-
ing on their cellular localization. Cellular membranes consist of
a wide variety of phospholipids that are substrates for PLA2
enzymes with different affinities. Two factors affect the activity
of a PLA2 enzyme toward a particular phospholipid substrate
including the association of the enzyme with the membrane
and the specific binding of the phospholipid in the active site.
To study the effect of the interfacial association with the
membrane on dose−response inhibition studies, a more
complex system of an equal molar mixture of five phospholipid
species was used to determine XI(50) values. The sn-1 and sn-
2 positions of each phospholipid contained palmitic (P) and
arachidonic (A) acid, respectively, whereas the head groups
were varied including phosphatidic acid (PA), phosphocholine
(PC), phosphoethanolamine (PE), PG, or phosphoserine
Figure 5. Dose−response inhibition curves for Ly315920 using PAPG substrate. (A) Activity of sPLA2 was measured by detecting 16:0 LPG in a
positive ion mode and (B) by detecting free AA in a negative ion mode.
Figure 6. Dose−response inhibition curves of OTFP using PLPC substrate. (A) Activity of iPLA2 was measured by detecting 16:0 LPC in a
positive ion mode and (B) by detecting free LA in a negative ion mode.
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(PS). The XI(50) values of pyrrophenone and OTFP,
determined in positive ion mode, were similar for each of
the five phospholipids individually with some variations
because of human and instrumental error (Figures 7A and
8A). XI(50) values based on total AA released of 0.0018 (IC50
= 1.30 μM) and 0.00007 (IC50 = 0.050 μM) were determined
for pyrrophenone and OTFP, respectively, which do not differ
significantly from the ones determined for each phospholipid
separately in a positive ion mode (Figures 7B and 8B).
According to the substrate specificity data, cPLA2 and iPLA2
did not exhibit significant preference for the phospholipid
headgroup;10 thus, the XI(50) values of pyrrophenone and
OTFP were not affected significantly in mixtures. In contrast,
as previously reported, sPLA2 showed strong preference for
PAPG compared to the other four phospholipid species.10 For
Ly315920, an XI(50) value of 0.0031 (IC50 = 2.14 μM) was
determined for PAPG as a substrate which is significantly
higher than the XI(50) values for the other four phospholipids
Figure 7. Dose−response inhibition curves for pyrrophenone using an equal molar mixture of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphate
(PAPA), PAPC, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (PAPE), PAPG, and PAPS as a substrate. (A) Activity of cPLA2
was measured by detecting 16:0 LPA, 16:0 LPC, 16:0 LPE, 16:0 LPG, and 16:0 LPS in a positive ion mode and (B) by detecting free AA in a
negative ion mode.
Figure 8. Dose−response inhibition curves for OTFP using an equal molar mixture of PAPA, PAPC, PAPE, PAPG, and PAPS as a substrate. (A)
Activity of iPLA2 was measured by detecting 16:0 LPA, 16:0 LPC, 16:0 LPE, 16:0 LPG, and 16:0 LPS in a positive ion mode and (B) by detecting
free AA in a negative ion mode.
Figure 9. Dose−response inhibition curves for Ly315920 using a mixture of PAPA, PAPC, PAPE, PAPG, and PAPS as a substrate. (A) Activity of
sPLA2 was measured by detecting 16:0 LPA, 16:0 LPC, 16:0 LPE, 16:0 LPG, and 16:0 LPS in a positive ion mode and (B) by detecting free AA in
a negative ion mode.
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(Figure 9A). By detecting AA in a negative ion mode, a total
composite XI(50) value was determined for the phospholipid
mixture because this FA is common in all five phospholipids.
An XI(50) value of 0.0008 (IC50 = 0.60 μM) was determined
for Ly315920, which differs from the ones determined for each
of the five phospholipids using a positive ion mode (Figure
9B). Furthermore, the XI(50) values for PAPS and PAPA (the
least good substrates) are higher than those for PAPE and
PAPC, the next best substrates, and lowest for PAPG, the best
substrate, in the order expected. This demonstrates that one
can enlarge the dynamic range of experimentally determining
inhibition constants by judicious choice of substrate and
substrate mixtures.
Application of PLA2 Assay Combined with Molecular
Dynamics to Identify Novel Inhibitors. Elucidating the
biological function of cPLA2, iPLA2, and sPLA2 is very
important because they are involved in several inflammatory
diseases including cancer, diabetes, and atherosclerosis.1 Small
organic molecules with potent and selective inhibitory
properties are essential tools for studying the biological
function of these enzymes. This in vitro assay can be combined
with in silico screening techniques to identify new hit
compounds for each enzyme. Because the available three-
dimensional structures of these enzymes do not contain a
bound inhibitor, molecular docking was employed to create an
initial enzyme−inhibitor complex that was consistent with
previously published HD-XMS data.12,15,16 Each complex was
then placed on the surface of the membrane based on previous
models for each enzyme binding to membranes.10 In the
context of the relaxed complex scheme, which combines the
advantages of molecular docking with dynamic structural
information,17 each system was subjected to molecular
dynamics (MD) simulations in the presence of a membrane.
Movies 1, 2, and 3 show the binding interaction of
pyrrophenone, OTFP, and Ly315920 in the active site of
cPLA2, iPLA2, and sPLA2, respectively. Clustering analysis
allowed the identification of dynamic structures for each
enzyme (Figure 10A−C). These structures will be used to
virtually screen compound libraries, select a reasonable number
of good binders, and test them in vitro using the PLA2 LC−MS
assay described herein. Even though cPLA2, iPLA2, and sPLA2
can bind and hydrolyze the same phospholipid substrate,
cPLA2 binds large inhibitors similar to pyrrophenone, whereas
iPLA2 and sPLA2 bind relatively small inhibitors such as OTFP
and Ly312059. The volume of the cPLA2 active site was
stabilized at ∼900 Å3 during the simulation, whereas the
volume of the iPLA2 and sPLA2 active site was stabilized at
∼500 Å3 (Figure 10D). This indicates that iPLA2 and sPLA2
can adjust the volume of their active site by recruiting small
molecule inhibitors that optimize interactions with small
binding pockets.
■ CONCLUSIONS
Assaying PLA2 enzymes using traditional radioactive assays has
been extremely limiting because radiolabeled phospholipid
substrates are challenging to synthesize and purify and few are
available commercially. In this article, we present a novel
lipidomics PLA2 assay which is simple, semi-high throughput,
and does not require the use of radiolabeled phospholipid. The
LC−MS-based system described herein has a sensitivity similar
to the radioactive assay. The new assay was validated by using
pyrrophenone, OTFP, and Ly315920, which are potent
inhibitors for cPLA2, iPLA2, and sPLA2, respectively. Because
detailed dose−response inhibition studies proved the robust-
ness of the assay, it is now possible to use it with mixtures of
phospholipids and in combination with in silico screening to
identify novel PLA2 inhibitors.
In the classic radiolabeled assay, the radiolabeled substrate is
used as a tracer for a particular phospholipid which is present
(i.e., 1-palmitoyl-2-(1-[14C]-arachidonoyl)-sn-glycero-3-phos-
phocholine for PAPC); therefore, if a mixture of phospholipids
was included as a substrate, the hydrolysis of the radiolabeled
substrate would be competing with other nonlabeled
phospholipids as a substrate, so the apparent activity would
depend on the specific phospholipid mixture used. In contrast
with the lipidomics assay, the specific lysophospholipid and the
specific FA products can each be detected for each different
phospholipid in the mixture. This is illustrated in Figures 7 and
8 whereby in the presence of an inhibitor, the net activity
(expressed as XI(50) or IC50) reflects the inhibitor binding to
the enzyme effecting its affinity for each substrate phospholipid
proportionally. For these two enzymes (cPLA2 and iPLA2),
each of the five substrates in the mixture has a similar affinity
for the enzyme; therefore, the XI(50) or IC50 are the same,
measured for each lysophospholipid product and for the total
AA released from all five phospholipids. In contrast, in Figure 9
Figure 10. MD simulations and clustering analysis allowed the identification of dynamic structures suitable for in silico screening of compound
libraries for (A) cPLA2, (B) iPLA2, and (C) sPLA2. (D) Active site volume during the time of the simulation for cPLA2, iPLA2, and sPLA2 is shown.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01568
J. Med. Chem. 2019, 62, 1999−2007
2004
with sPLA2, where the affinity for each phospholipid substrate
is different, the XI(50) or IC50 for the sPLA2 specific inhibitor
is different for each phospholipid. If one of the phospholipids
in the mixture was not a substrate for the enzyme as might be
the case in a natural membrane, then no lysophospholipid or
FA products would appear for that phospholipid, but one
could still determine the XI(50) or IC50 for the inhibition of
the enzyme acting on each of the other phospholipids present.
Additionally, it is important to test inhibitors on natural
substrates found in the membrane of the specific subcellular
organelle that each enzyme acts on. Mixtures of phospholipids
with varying sn-2 FA leaving groups and polar groups can now
be combined to mimic natural membranes, and the resulting
activity of each PLA2 can be determined. This new approach to
assaying PLA2s will allow us to determine if a given inhibitor is
more effective with one substrate over another. We are now
exploring the extension of this in vitro assay to determine the
ex vivo activity of these enzymes in living cells, where the
analysis of the products after enzyme activation in the cells
should provide greater insight as to the relevance to the in vivo
activity.
■ EXPERIMENTAL AND COMPUTATIONAL
METHODS
Lipidomics PLA2 Assay. Group-specific assays were employed to
determine the activity of human recombinant group IVA cytosolic
(cPLA2), group VIA calcium-independent (iPLA2), and group V
secreted PLA2 (sPLA2) in a mixed micelle 96 well-plate assay, as
previously described.10 The substrate for each enzyme consisted of
100 μM of phospholipid, 400 μM of C12E8 surfactant, 2.5 μM of
17:0 LPC, and 10 μM AA-d8 internal standards for positive and
negative ion modes, respectively. For cPLA2, the total phospholipid
concentration (100 μM) consisted of 97 μM phospholipid substrate
and 3 μM PI(4,5)P2, which enhances the activity of the enzyme. A
specific buffer was prepared to achieve optimum activity for each
enzyme. The buffer for cPLA2 contained 100 mM HEPES of pH 7.5,
90 μM CaCl2, and 2 mM DTT. For iPLA2, the buffer consisted of 100
mM HEPES of pH 7.5, 2 mM ATP, and 4 mM DTT. Finally, the
buffer for sPLA2 contained 50 mM Tris-HCl of pH 8.0 and 5 mM
CaCl2. The enzymatic reaction was performed in a 96-well plate using
a Benchmark Scientific H5000-H MultiTherm heating shaker for 30
min at 40 °C. Each reaction was quenched with 120 μL of methanol/
acetonitrile (ACN; 80/20, v/v), and the samples were analyzed using
the HPLC−MS system. A blank experiment, which did not contain
enzyme, was also included for each substrate to determine the
nonenzymatic hydrolysis product and to detect any changes in the
intensity of both 17:0 LPC and AA-d8 internal standards. For each
inhibitor dose−response curve, three replicates were performed for
each inhibitor concentration during three independent experiments.
The standard deviation was calculated for each triplicate and is
included in each graph with error bars. Each inhibitor was dissolved in
dimethyl sulfoxide at a 5 mM concentration. The radioactive assay
was extensively described in previous publications.12,16 Dose−
response inhibition curves were generated using GraphPad Prism
5.0 and the nonlinear regression by plotting percentage of inhibition
versus log (mole fraction) or log (concentration) to calculate the
reported XI(50) and IC50 values and their associated error.
High-Performance Liquid Chromatography−Mass Spectrome-
try/Mass Spectrometry. A Shimadzu HPLC system consisting of a
system controller (SCL-10Avp) with two HPLC pumps (LC-
10ADvp), a CTC Analytics PAL autosampler platform (Leap
Technologies), and a column controller instrument (Analytical Sales
& Products, Inc) were employed for the LC analysis. Mass
spectrometric analysis was performed using an AB Sciex 4000
QTRAP triple quadrupole/linear ion trap hybrid mass spectrometer
equipped with a Turbo V ion source.10
Chromatography (HPLC). For separation and quantification of the
lysophospholipids, a Phenomenex Kinetex 2.6 μm HILIC 100 Å
column of 30 × 2.1 mm size was used. The binary gradient consisted
of (A) ACN/water (95/5, v/v, pH = 8.0) containing 25 mM AcNH4
and (B) ACN/water (50/50, v/v, pH = 7.5) containing 25 mM
AcNH4. Gradient elution was carried out for 1.6 min at a flow rate of
0.8 mL/min. Gradient conditions were as follows: 0% B for 0.8 min;
0−100% B for 0.4 min; 100% B for 0.3 min; and 100% B for 0.1
min.10 For separation and quantification of free FAs, a Phenomenex
Kinetex 2.6 μm C18 100 Å column of 30 × 2.1 mm size was used. A
mobile phase of ACN/water (80/20, v/v, pH = 8.9) containing 10
mM NH4HCO3 was used in an isocratic elution. A 10 μL aliquot of
each sample was injected into the column. The column temperature
was kept at 40 °C. All samples were maintained at 4 °C throughout
the analysis.
Mass Spectrometry. Lysophospholipids (primary and internal
standards), phospholipids, and surfactants (C12E8) were detected in
a positive electrospray ionization (ESI) mode, whereas free FAs in a
negative ESI mode. Molecular species were detected as [M + H]+ ions
in the positive ion mode and as [M − H]− ions in the negative ion
mode. Curtain gas (CUR), nebulizer gas (GS1), and turbo gas (GS2)
were set to 10, 50, and 20 psi, respectively. The electrospray voltage
was set to +4.5 or −4.5 kV, and the turbo ion spray source
temperature was set to 500 °C. Lysophospholipids were analyzed
using scheduled MRM. Declustering potentials and collision energies
were optimized for each analyte to achieve optimal mass
spectrometric detection. Nitrogen was employed as the collision
gas. Data acquisitions were performed using Analyst software.
MultiQuant software was used to quantify all metabolites.
Reagents. Pyrrophenone was purchased from Cayman Chemical
Company and was stated to be 100% pure based on HPLC and TLC.
OTFP was synthesized by Dr. Bruce Hammock’s group and was
stated to be more than 97% pure based on GC, NMR, and TLC.18
Ly315920 was purchased from Selleckchem and was stated to be
more that 99% pure based on NMR and HPLC. Phospholipids,
primary standards, and internal standards were purchased from Avanti
Polar Lipids, Inc. Optima LC−MS grade ACN, water (H2O), and
HPLC grade ammonium acetate (AcNH4) were obtained from Fisher
Scientific. HPLC great ammonium bicarbonate (NH4HCO3) was
obtained from Spectrum Chemical Mfg. Corp. Octaethylene glycol
monododecyl ether (C12E8) was obtained from Sigma-Aldrich.
MD Simulations. Enzyme−Inhibitor−Membrane Complexes.
Initial complexes of each enzyme with pyrrophenone, OTFP, and
Ly315920 were generated using molecular docking.19 The crystal
structure of cPLA2,
20 a previously published homology model of
iPLA2 based on patatin,
2 and a previously published homology model
of GV sPLA2 based on GIIA sPLA2 were used for docking.
10 The
calculations were performed using a previously published docking
protocol.12,16 The Membrane Builder implemented in CHARMM-
GUI was employed to generate enzyme−inhibitor−membrane models
for MD simulations.21,22 As previously reported, the membrane patch
consisted of POPC, SAPC, POPE, POPA, POPG, POPS, SAPI(4,5)-
P2, and cholesterol. The average ratios of the phospholipids were
chosen to be 0.48 for PC, 0.27 for PE, 0.10 for PI(4,5)P2, 0.06 for PS,
and 0.09 for PA and PG. The average cholesterol/phospholipid ratio
was chosen to be 0.40. These ratios are the average ratio of the
nuclear, mitochondrial, and plasma membranes where cPLA2, iPLA2,
and sPLA2 are localized, respectively.
23−26 Each system was solvated
with TIP3P water molecules and neutralized with 150 mM sodium
chloride (NaCl) using the Visual MD (VMD) package.27
Equilibration and Production Runs. MD simulations were carried
out using NAMD 2.12.28 The following minimization and
equilibration protocol was performed, as previously described:10 a
minimization of 80 000 steps was initially performed by applying
harmonic constraints on the enzyme−inhibitor−membrane that were
gradually turned off using a constraint scaling factor, followed by a
second 120 000 steps minimization without constraints. An initial
equilibration of 10 000 steps was performed by also applying
harmonic constraints on the enzyme−inhibitor−membrane that
were gradually turned off using the same constraint scaling factor,
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followed by a second 10 000 steps equilibration without constraints.
During the equilibration, each system was slowly heated and held to
310 K using temperature reassignment with a reassignment frequency
of 500 timesteps (1000 fs) and a reassignment increment of 1 K. The
above minimization and equilibration protocol was sufficient to
induce an appropriate disorder of a fluidlike bilayer and avoid
unnatural atomistic positions and failure of the simulations by atoms
moving at very high velocities. Each system was finally subjected to a
1 μs production run. For each production run, the temperature was
maintained at 310 K using the Langevin thermostat with Langevin
coupling coefficient of 1/ps.29 The NPT ensemble was employed, and
the pressure was kept constant at 1.01325 kPa using the Langevin
piston method with the “useGroupPressure”, “useFlexibleCell”, and
“useConstantArea” parameters turned on.30 A timestep of 2 fs was
used in combination with the SHAKE algorithm to hold the bonds of
hydrogen atoms similarly constrained.31 Nonbonded interactions and
full electrostatics were calculated for every 1 and 2 timesteps,
respectively. Switching functions are used to smoothly take electro-
static and van der Waals interactions to zero with a switching distance
of 10 Å and a cutoff of 12 Å. Long-range electrostatic forces in the
periodic system were evaluated using the particle mesh Ewald Sum
method with a grid spacing of 1/Å.32 The CHARMM General Force
Field (CGenFF) and the CHARMM36 all-atom additive force field
and parameters were used for other simulations.33,34
Binding Pocket Volume Calculations. The POVME algorithm was
employed for calculating the volume of the binding pocket of each
enzyme over the time of each simulation.10,35 A total number of 6252
frames from each simulation trajectory was used for the calculations.
The frames were aligned on the initial complex that was used to carry
out the simulation using VMD and were saved in a multiframe PDB
format. To define the “inclusion sphere” that entirely encloses the
binding pocket of each enzyme, the center of mass of the residues
within 5 Å around the bound inhibitor was used as the x, y, and z
coordinates of the sphere. An “inclusion sphere” radius of 11 Å was
used. Equidistant points were generated in POVME using a grid
spacing of 1 Å and a distance cutoff of 1.09 Å.
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